Preliminary Safety and Efficacy Results From a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic Post author:andrewkaretas Post published:November 9, 2026 Post category:Dual/Scientific Publications CAR T-Cell Therapy for Autoimmune Disease Continue ReadingPreliminary Safety and Efficacy Results From a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases Post author:andrewkaretas Post published:November 18, 2024 Post category:Dual/Scientific Publications Continue ReadingPreclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Preclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR Post author:andrewkaretas Post published:November 2, 2023 Post category:Dual/PLATFORM/Scientific Publications Continue ReadingPreclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR
